↓ Skip to main content

Dove Medical Press

Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta

Overview of attention for article published in Neuropsychiatric Disease and Treatment, September 2013
Altmetric Badge

Mentioned by

twitter
2 X users

Citations

dimensions_citation
14 Dimensions

Readers on

mendeley
47 Mendeley
Title
Review of the pharmacoeconomics of early treatment of multiple sclerosis using interferon beta
Published in
Neuropsychiatric Disease and Treatment, September 2013
DOI 10.2147/ndt.s33949
Pubmed ID
Authors

Florian Castrop, Bernhard Haslinger, Bernhard Hemmer, Dorothea Buck

Abstract

Multiple sclerosis (MS) is a common neurological disease with increasing incidence and prevalence. Onset of disease is most frequently in young adulthood when productivity is usually highest; it is of chronic nature and, in the majority of patients, it will result in accumulation of disability. Due to loss of productivity in patients and caregivers as well as high expenses for medical treatment, MS is considered a disease with high economic burden for patients and society. Several drugs have been approved for treatment of MS. While treatment ameliorates the course of the disease, it is very costly; therefore, pharmacoeconomics, evaluating costs and effects of disease-modifying treatment in MS, has become an important issue. Here, we review the economic impact and treatment strategies of MS and discuss recent studies on pharmacoeconomics of early treatment with interferon beta.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 47 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 2%
Turkey 1 2%
Brazil 1 2%
Unknown 44 94%

Demographic breakdown

Readers by professional status Count As %
Researcher 7 15%
Other 7 15%
Student > Bachelor 5 11%
Student > Ph. D. Student 5 11%
Student > Master 5 11%
Other 11 23%
Unknown 7 15%
Readers by discipline Count As %
Medicine and Dentistry 14 30%
Agricultural and Biological Sciences 5 11%
Biochemistry, Genetics and Molecular Biology 4 9%
Nursing and Health Professions 3 6%
Immunology and Microbiology 2 4%
Other 9 19%
Unknown 10 21%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 September 2013.
All research outputs
#17,285,668
of 25,373,627 outputs
Outputs from Neuropsychiatric Disease and Treatment
#1,902
of 3,132 outputs
Outputs of similar age
#134,088
of 212,473 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#46
of 67 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,132 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one is in the 30th percentile – i.e., 30% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 212,473 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 27th percentile – i.e., 27% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 67 others from the same source and published within six weeks on either side of this one. This one is in the 11th percentile – i.e., 11% of its contemporaries scored the same or lower than it.